European Commission Approves Pfizer’s Cibinqo^® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis

Pfizer, Inc. announced that the European Commission has approved the 100 mg and 200 mg doses of Cibinqo®, an oral, once-daily, Janus kinase 1 inhibitor, for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.